Erglis Andrejs, Narbute Inga, Kumsars Indulis, Jegere Sanda, Mintale Iveta, Zakke Ilja, Strazdins Uldis, Saltups Andris
Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
J Am Coll Cardiol. 2007 Aug 7;50(6):491-7. doi: 10.1016/j.jacc.2007.03.055. Epub 2007 Jul 23.
To optimize percutaneous coronary intervention (PCI) strategy for unprotected left main (LM) disease, we performed a randomized study: intravascular ultrasound (IVUS)-guided bare-metal stent (BMS) or paclitaxel-eluting stent (PES) implantation after lesion pre-treatment with cutting balloon (CB) for unprotected LM lesions.
Recent studies have shown promising results in terms of safety and feasibility for patients with LM disease who underwent PCI with stent implantation. However, comparison of BMS and PES for LM lesions has not yet been evaluated.
One hundred three patients were randomly assigned to receive BMS (n = 50) or PES (n = 53) implantation. All interventions were IVUS guided, and CB pre-treatment before stenting was performed in all patients. All patients were scheduled for 6-month follow-up.
Baseline clinical characteristics were comparable in both cohorts. Stent implantation was successful in all lesions. Follow-up analysis showed binary restenosis in 11 (22%) BMS and in 3 (6%) PES patients (p = 0.021). By IVUS, percentage of neointimal volume obstruction at 6 months was reduced from 25.20 +/- 22.02% with BMS to 16.60 +/- 17.25% with PES (p = 0.02). At 6 months, the major adverse cardiac event-free survival rate was 70% in BMS and 87% in PES patients (p = 0.036).
This study demonstrates that PCI of LM with IVUS guidance and CB pre-treatment is safe and effective. No serious procedure-related complications were observed, and clinical outcomes appeared to be good. Finally, the findings demonstrate that implantation of PES may be superior to BMS in the large-diameter LM vessel at 6 months, warranting the performance of a large-scale randomized trial.
为优化无保护左主干(LM)病变的经皮冠状动脉介入治疗(PCI)策略,我们开展了一项随机研究:对于无保护LM病变,在使用切割球囊(CB)对病变进行预处理后,行血管内超声(IVUS)引导下的裸金属支架(BMS)或紫杉醇洗脱支架(PES)植入术。
近期研究表明,接受支架植入PCI治疗的LM病变患者在安全性和可行性方面取得了令人鼓舞的结果。然而,尚未对LM病变的BMS和PES进行比较评估。
103例患者被随机分配接受BMS植入(n = 50)或PES植入(n = 53)。所有干预均在IVUS引导下进行,所有患者在支架置入前均进行CB预处理。所有患者均计划进行6个月的随访。
两组患者的基线临床特征具有可比性。所有病变的支架植入均成功。随访分析显示,11例(22%)BMS患者和3例(6%)PES患者出现二元再狭窄(p = 0.021)。通过IVUS检查,6个月时新生内膜体积阻塞百分比从BMS组的25.20±22.02%降至PES组的16.60±17.25%(p = 0.02)。6个月时,BMS组主要不良心脏事件无生存率为70%,PES组为87%(p = 0.036)。
本研究表明,IVUS引导下并经CB预处理的LM病变PCI治疗安全有效。未观察到严重的手术相关并发症,临床结果似乎良好。最后,研究结果表明,在6个月时,大直径LM血管中PES植入可能优于BMS,这值得开展大规模随机试验。